Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients

Shahrzad Mokhtari, Shakiba Houshi, Omid Mirmosayyeb, Mahdi Barzegar, Alireza Afshari-Safavi, Majid Ghasemi, Vahid Shaygannejad


Background: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, immune‑mediated disease of the central nervous system. It is still unestablished whether heredity correlates with the disease’s progression and severity. Methods: This study includes the patients with MS seen in the MS clinic of Kashani Hospital, affiliated with Isfahan University of Medical Sciences, from January 2019 to January 2020. We gathered data regarding the demographic and clinical characteristics, such as type of disease and family history of MS. Patients were grouped based on having relatives with MS. We compared demographic and clinical characteristics between those with a family history of MS (familial MS: FMS) and those without a family history of MS (sporadic MS: SMS). Results: We included 2,929 MS patients, 523 (17.2%) with FMS and 2,406 (82.8%) with SMS. Patients with FMS were found to have active lesions in the thoracic spine more frequently than those with SMS (P = 0.022). We also found differences in the distribution of gender (P = 0.036) and the frequency of having active brain lesions (P = .024) among patients with FMS and SMS. No difference was found between the demographic/clinical characteristics and the number of affected relatives in the family. Conclusions: Significant differences were found among different groups of patients in terms of demographical and clinical characteristics.


Familial multiple sclerosis; magnetic resonance imaging; multiple sclerosis


Mirmosayyeb O, Brand S, Barzegar M, Afshari‑Safavi A,

Nehzat N, Shaygannejad V, et al. Clinical characteristics

and disability progression of early‑ and late‑onset multiple

sclerosis compared to adult‑onset multiple sclerosis. J Clin Med


Mirmosayyeb O, Barzegar M, Nehzat N, Najdaghi S, Ansari B,

Shaygannejad V. Association of helicobacter pylori with multiple

sclerosis: Protective or risk factor?. Curr J Neurol 2020;19:59‑66.

Moss BP, Rensel MR, Hersh CM. Wellness and the role

of comorbidities in multiple sclerosis. Neurotherapeutics


Kalron A, Aloni R, Givon U, Menascu S. Fear of falling, not

falls, impacts leisure‑time physical activity in people with

multiple sclerosis. Gait Posture 2018;65:33‑8.

Nasiri M, Maroufi H, Sahraian MA, Eskandarieh S. Prevalence

of multiple sclerosis and its risks in Tehran, Iran, in 2019. Neurol

Sci 2021;42:2575‑6.

Heydarpour P, Khoshkish S, Abtahi S, Moradi‑Lakeh M,

Sahraian MA. Multiple sclerosis epidemiology in middle east

and north Africa: A systematic review and meta‑analysis.

Neuroepidemiology 2015;44:232‑44.

Karussis D. The diagnosis of multiple sclerosis and the various

related demyelinating syndromes: A critical review. J Autoimmun 2014;48‑49:134‑42.

Westerlind H, Boström I, Stawiarz L, Landtblom AM,

Almqvist C, Hillert J. New data identify an increasing sex ratio

of multiple sclerosis in Sweden. Mult Scler 2014;20:1578‑83.

Ashtari F, Shaygannejad V, Heidari F, Akbari M. Prevalence of

familial multiple sclerosis in Isfahan, Iran. J Isfahan Med Sch


Ramagopalan SV, Sadovnick AD. Epidemiology of multiple

sclerosis. Neurol Clin 2011;29:207‑17.

Seboun E, Oksenberg JR, Rombos A, Usuku K, Goodkin DE,

Lincoln RR, et al. Linkage analysis of candidate myelin genes in

familial multiple sclerosis. Neurogenetics 1999;2:155‑62.

McDonnell GV, Mawhinney H, Graham CA, Hawkins SA,

Middleton D. A study of the HLA‑DR region in clinical

subgroups of multiple sclerosis and its influence on prognosis.

J Neurol Sci 1999;165:77‑83.

Qiu W, James I, Carroll WM, Mastaglia FL, Kermode AG.

HLA‑DR allele polymorphism and multiple sclerosis in Chinese

populations: A meta‑analysis. Mult Scler 2011;17:382‑8.

Duquette P, Décary F, Pleines J, Boivin D, Lamoureux G,

Cosgrove JB, et al. Clinical sub‑groups of multiple sclerosis

in relation to HLA: DR alleles as possible markers of disease

progression. Can J Neurol Sci 1985;12:106‑10.

van Luijn MM, Kreft KL, Jongsma ML, Mes SW,

Wierenga‑Wolf AF, van Meurs M, et al. Multiple

sclerosis‑associated CLEC16A controls HLA class II expression

via late endosome biogenesis. Brain 2015;138:1531‑47.

Balnyte R, Rastenyte D, Vaitkus A, Mickeviciene D,

Skrodeniene E, Vitkauskiene A, et al. The importance of HLA

DRB1 gene allele to clinical features and disability in patients

with multiple sclerosis in Lithuania. BMC Neurol 2013;13:77.

Andrijauskis D, Balnyte R, Keturkaite I, Vaitkus A. Clinical and

diagnostic features of patients with familial multiple sclerosis.

Med Hypotheses 2019;131:109310.

Nielsen NM, Westergaard T, Rostgaard K, Frisch M, Hjalgrim H,

Wohlfahrt J, et al. Familial risk of multiple sclerosis:

A nationwide cohort study. Am J Epidemiol 2005;162:774‑8.

Herrera BM, Ramagopalan SV, Lincoln MR, Orton SM,

Chao MJ, Sadovnick AD, et al. Parent‑of‑origin effects in MS:

Observations from avuncular pairs. Neurology 2008;71:799‑803.

Roxburgh RH, Seaman SR, Masterman T, Hensiek AE,

Sawcer SJ, Vukusic S, et al. Multiple sclerosis severity score:

Using disability and disease duration to rate disease severity.

Neurology 2005;64:1144‑51.

Koch M, Zhao Y, Yee I, Guimond C, Kingwell E, Rieckmann P,

et al. Disease onset in familial and sporadic primary progressive

multiple sclerosis. Mult Scler 2010;16:694‑700.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA,

Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010

revisions to the McDonald criteria. Ann Neurol 2011;69:292‑302.

De Stefano N, Battaglini M, Smith SM. Measuring brain atrophy

in multiple sclerosis. J Neuroimaging 2007;17 Suppl 1:10S‑15S.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis:

An expanded disability status scale (EDSS). Neurology


Verma JP, Data analysis in management with SPSS software.

Springer Science & Business Media, 2012.

Saadatnia M, Etemadifar M, Maghzi AH. Multiple sclerosis in

Isfahan, Iran. Int Rev Neurobiol 2007;79:357‑75.

Toghianifar N, Etemadifar M, Sharifzadeh A, Nasr Z.

Characteristics of familial multiple sclerosis in Isfahan, Iran:

A cross‑sectional study. Neurol Asia 2014;19.

AlJumah M, Otaibi HA, Al Towaijri G, Hassan A, Kareem A,

Kalakatawi M, et al. Familial aggregation of multiple sclerosis:

Results from the national registry of the disease in Saudi Arabia.

Mult Scler J Exp Transl Clin 2020;6:2055217320960499.

Salehi Z, Almasi‑Hashiani A, Sahraian MA, Eskandarieh S.

Epidemiology of familial multiple sclerosis: A population‑based

study in Tehran during 1999‑2018. Mult Scler Relat Disord


Talebi M, Sadigh‑Eteghad S, Sahraian MA, Fahidi A. Age

and sex adjusted prevalence and annual incidence of multiple

sclerosis in East‑Azerbaijan, Iran. Mult Scler Relat Disord


Ceccarelli A, Mifsud VA, Dogar A. Demographic and clinical

characteristics of familial and sporadic multiple sclerosis:

A single center exploratory study from Abu Dhabi. J Clin

Neurosci 2020;76:145‑7.

Rojas JI, Patrucco L, MIguez J, Sinay V, Cassara FP, Cáceres F,

et al. Disease onset in familial and sporadic multiple sclerosis in

Argentina. Mult Scler Relat Disord 2016;6:54‑6.

Regal AR, Garcia LA, Dopazo MS, Jorrín M del CA. Familial

multiple sclerosis: An epidemiological study in Pontevedra,

Spain. (P2.396). AAN Enterprises, 2018;90.

Steenhof M, Stenager E, Nielsen NM, Kyvik K, Möller S,

Hertz JM. Familial multiple sclerosis patients have a shorter

delay in diagnosis than sporadic cases. Mult Scler Relat Disord


Ebers GC, Koopman WJ, Hader W, Sadovnick AD,

Kremenchutzky M, Mandalfino P, et al. The natural history

of multiple sclerosis: A geographically based study: 8. Brain

;123 Pt 3:641‑9.

Katsavos S, Artemiadis A, Davaki P, Stamboulis E, Kilindireas K,

Anagnostouli M. Familial multiple sclerosis in greece: Distinct

clinical and imaging characteristics in comparison with the

sporadic disease. Clin Neurol Neurosurg 2018;173:144‑9.